Key result
Transcatheter aortic valve implantation shows encouraging long-term outcomes in high-risk patients, with survival rates ranging from 62-74% at 2 years and 56-61% at 3 years.
Why the study?
What are the long-term survival and clinical outcomes after transcatheter aortic valve implantation in patients at high risk for surgical aortic valve replacement?
What are the long-term survival and clinical outcomes after transcatheter aortic valve implantation in patients at high risk for surgical aortic valve replacement?
TAVI shows encouraging long-term survival and sustained clinical improvement up to 3 years in high-risk patients, though paravalvular leakage remains a concern.
Transcatheter aortic valve implantation (TAVI) is evolving rapidly as a therapeutic option in patients deemed to be at high risk for surgical aortic valve replacement. Early outcome and survival of controlled feasibility trials and single- center experience with TAVI have been previously reported. Valve performance and hemodynamics seem to improve significantly after TAVI. Long-term outcome up to 3 years have been demonstrated in recent studies. Admittedly, the results are encouraging with a survival rate at 2 and 3 years ranging from 62 to 74% and from 56 to 61% respectively. The improvement in hemodynamical and clinical status sustained beyond the 3 years follows up. However, paravalvular leakage after TAVI remains an important issue in this rapidely evolving field.
No takes yet. Share an insight, caveat, or question.
Elhmidi et al. (2014) conducted a review in High risk for surgical aortic valve replacement. Transcatheter aortic valve implantation (TAVI) was evaluated on Survival rate at 2 and 3 years. Transcatheter aortic valve implantation shows encouraging long-term outcomes in high-risk patients, with survival rates ranging from 62-74% at 2 years and 56-61% at 3 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: